CL2009000809A1 -
Pharmaceutical composition comprising a dpp4 inhibitor 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino-piperidin-1-yl) -xanthine and metformin or its salts, together with l-arginine to stabilize the dpp4 inhibitor; procedure for preparing said composition.
- Google Patents
Pharmaceutical composition comprising a dpp4 inhibitor 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino-piperidin-1-yl) -xanthine and metformin or its salts, together with l-arginine to stabilize the dpp4 inhibitor; procedure for preparing said composition.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filedlitigationCriticalhttps://patents.darts-ip.com/?family=66630027&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000809(A1)"Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filedfiledCritical
Publication of CL2009000809A1publicationCriticalpatent/CL2009000809A1/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Abstract
Composición farmacéutica que comprende un inhibidor de la dpp4 tal como vildagliptina, saxagliptina y alogliptina, un fármaco acompañante tal como una biguanida o una tiazolidinona, uno o más excipientes y un agente nucleofilo y/o básico para estabilizar dicho inhibidor de dpp4; y procedimiento de preparación de dicha composición.Pharmaceutical composition comprising a dpp4 inhibitor such as vildagliptin, saxagliptin and alogliptin, an accompanying drug such as a biguanide or a thiazolidinone, one or more excipients and a nucleophilic and / or basic agent to stabilize said dpp4 inhibitor; and process for preparing said composition.
CL2009000809A2008-04-032009-04-02
Pharmaceutical composition comprising a dpp4 inhibitor 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino-piperidin-1-yl) -xanthine and metformin or its salts, together with l-arginine to stabilize the dpp4 inhibitor; procedure for preparing said composition.
CL2009000809A1
(en)
Pharmaceutical composition comprising a dpp4 inhibitor 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino-piperidin-1-yl) -xanthine and metformin or its salts, together with l-arginine to stabilize the dpp4 inhibitor; procedure for preparing said composition.
Use of a pharmaceutical combination comprising 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino -piperidin-1-yl) -xanthine, metformin and defined excipients for the treatment and / or prevention of metabolic diseases, optionally in combination with one or more other active substances.
Aqueous pharmaceutical formulation containing an insulin, an insulin analog or an insulin derivative, or one of its pharmacologically tolerable salts, and methionine; process to prepare said formulation; medicine that contains it; and its use to treat diabetes mellitus.
Solid salts of 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7 (2butin-1-yl) 8- (3- (r) -amino-piperidin-1-yl) - xanthine and an acid in stoichiometry 1: 1; preparation procedure; pharmaceutical composition; and its use to treat or prevent a dpp-4 enzyme mediated disorder, such as type 2 diabetes mellitus.
Hydrochlorides of 1-[(3-cyanopyridin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-aminopiperidin-1-yl)xanthine, their use as medicaments and pharmaceutical composition
Oral pharmaceutical composition comprising time-controlled pulsatile release particles (tpr), containing a weakly basic poorly soluble drug and an organic acid separated by a sustained release layer, and rapid release particles (rr); capsule comprising it; and its use to treat emesis.
A COMPOSITION THAT INCLUDES 2-N-BUTIL-3- [4- (3-DI-N-BUTILAMINOPROPOXI) BENZOIL] -5-METILSULPHONAMIDE-BENZOFURAN AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
Pharmaceutical composition comprising a dpp4 inhibitor 1 - [(4-methyl-quinazolin-2-yl) methyl] -3-methyl-7- (2-butyn-1-yl) -8- (3- (r) -amino-piperidin-1-yl) -xanthine and metformin or its salts, together with l-arginine to stabilize the dpp4 inhibitor; procedure for preparing said composition.